Investigational drug · Phase 2
KC1086
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "KC1086"
First trial start
2026
Nov 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KC1086", any sponsor or status.
Conditions studied
As listed on its trial records.
- HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "KC1086" as an intervention, largest first.
- KC1086 in Combination With Fulvestrant for HR-Positive, HER2-Negative Advanced Breast CancerNot yet recruiting
Beijing Konruns Pharmaceutical Co., Ltd.Industry
NCT07937605 · 168 participants (planned) · Start Nov 2026 · Primary completion Nov 2029
Drug: KC1086; Fulvestrant and 3 more · For: HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
- A Study of KC1086 in Patients With Advanced Solid TumorsNot yet recruiting
Beijing Konruns Pharmaceutical Co., Ltd.Industry
NCT07118709 · 66 participants (planned) · Start Aug 2025 · Primary completion Aug 2028
Drug: KC1086 · For: Advanced Solid Tumors Cancer
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.